Aging can take a heavy toll on the hippocampus, the brain region central to learning and memory. Researchers at the University of California, San Francisco report they have identified a protein that may play an outsized role in that decline.
In a study published in Nature Aging, the team points to FTL1, a ferritin-related protein involved in iron handling, as a key molecular change seen in older mouse hippocampus. The researchers say shifting FTL1 levels altered memory performance and the strength of neural connections in ways that tracked with age.
A standout signal in aging brains
To pinpoint what changes over time, scientists compared gene and protein patterns in the hippocampus of young and older mice. Among many measurements, FTL1 emerged as the most consistent difference between age groups.
Older mice had higher FTL1 levels alongside fewer synaptic connections and worse results on cognitive tasks. The authors report that the pattern suggested more than a passive marker of aging, raising the possibility that FTL1 helps drive the process.
What happened when FTL1 was altered
When researchers increased FTL1 in young mice, the animals developed brain and behavioral changes resembling those seen in older mice. The hippocampus showed reduced connectivity, and performance on memory-related testing declined.
Cell experiments offered a potential explanation: neurons pushed to make more FTL1 formed simpler structures, with fewer branching extensions needed for complex signaling. That shift, the team argues, could help explain how elevated FTL1 weakens hippocampal circuitry.
Can memory decline be reversed?
In older mice, lowering FTL1 was linked to improved synaptic connections and better memory test performance. Senior author Saul Villeda said, “It is truly a reversal of impairments,” emphasizing that the effect went beyond delaying decline.
The group also reported a metabolic component, with higher FTL1 associated with slower energy use in hippocampal cells. In lab settings, boosting cellular metabolism with an experimental compound reduced the harmful effects tied to elevated FTL1, pointing to possible therapeutic angles.
Experts caution that mouse findings do not automatically translate to human brain aging, and any treatment approach would require extensive safety and efficacy testing. Still, the UCSF team argues that targeting FTL1 or related metabolic pathways could eventually open a new route for interventions aimed at age-related cognitive decline.
Leave a Reply